<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02228655</url>
  </required_header>
  <id_info>
    <org_study_id>FX-C-888</org_study_id>
    <nct_id>NCT02228655</nct_id>
  </id_info>
  <brief_title>An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD</brief_title>
  <official_title>An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FerruMax Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FerruMax Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FMX-8 is a new type of drug being tested for the treatment of anemia in chronic illnesses.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit patients meeting eligibilty criteria.
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin concentration</measure>
    <time_frame>57 day evaluation period</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Anemia in Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>FMX-8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FMX-8 for injection, 15mg/kg, twice weekly, 29 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMX-8</intervention_name>
    <arm_group_label>FMX-8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a documented hemoglobin level to be less than 10 g/dL at screening

          -  diagnoses of CKD 4 or 5

          -  body mass index (BMI) between 18 kg/m2 and 42 kg/m2, inclusive, based upon the height
             and weight at screening

          -  ferritin levels ≥100 ng/ml or Tsat ≥20% at screening

          -  erythropoietin (EPO) level greater than 8 ng/mL

          -  able to provide written informed consent

          -  able to understand and follow all trial procedures

          -  willing to use contraception as detailed in the protocol

        Exclusion Criteria:

          -  receipt of red blood cell (RBC) transfusion within four weeks before screening

          -  overt gastrointestinal bleeding or other bleeding episode that required transfusion
             within 2 months prior to screening

          -  infection necessitating antibiotic or anti-viral treatment within a month prior to
             screening

          -  requiring Coumadin (warfarin), Pradaxa®, Eliquis®, or Xarelto®

          -  hemoglobinopathies such as homozygous sickle-cell disease or thalassemias of all types

          -  active hemolysis or chronic hypoxia

          -  active malignant diseases (except non-melanoma skin cancer) or life expectancy less
             than 6 months

          -  chronic, uncontrolled or symptomatic inflammatory disease or non-renal cause of anemia
             such as rheumatoid arthritis, systemic lupus erythematosus, HIV, or systemic acute
             infection

          -  on immunosuppressive therapeutics except topical corticosteroids or nasal sprays

          -  chronic congestive heart failure (New York Heart Association Class III, IV)

          -  significant hypertension (≥90 diastolic) based on a sitting diastolic blood pressure
             at screening

          -  kidney transplant within the past year: patients who are off immunosuppressive agents
             following a failed transplant are eligible for the trial

          -  end-stage liver disease

          -  known hypersensitivity to recombinant protein therapies

          -  female patients who are pregnant or breast feeding

          -  previous exposure to FMX-8

          -  previous exposure to Epogen®, Procrit® (erythropoietin) Aranesp® (darbepoietin alpha),
             Omontys® or Hematide® (peginesatide) anemia treatment

          -  uncontrolled hyperparathyroidism (PTH &gt;750) based upon latest PTH determination within
             the past 4 months

          -  inability to comply with the trial scheduled visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stewart Lecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006 May;38(5):531-9. Epub 2006 Apr 9.</citation>
    <PMID>16604073</PMID>
  </reference>
  <reference>
    <citation>Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007 Jul;117(7):1933-9.</citation>
    <PMID>17607365</PMID>
  </reference>
  <reference>
    <citation>Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. J Clin Invest. 2005 Aug;115(8):2187-91.</citation>
    <PMID>16075059</PMID>
  </reference>
  <reference>
    <citation>KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007 Sep;50(3):471-530.</citation>
    <PMID>17720528</PMID>
  </reference>
  <reference>
    <citation>Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, Willenbacher W, Eller K, Wolf D, Seifert M, Sun CC, Babitt JL, Hong CC, Menhall T, Gearing P, Lin HY, Weiss G. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood. 2011 Nov 3;118(18):4977-84. doi: 10.1182/blood-2011-03-345066. Epub 2011 Jul 5.</citation>
    <PMID>21730356</PMID>
  </reference>
  <reference>
    <citation>Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005 Mar 10;352(10):1011-23. Review.</citation>
    <PMID>15758012</PMID>
  </reference>
  <reference>
    <citation>Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007 Apr;13(3 Suppl):S1-9. Review.</citation>
    <PMID>17402808</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>CKD</keyword>
  <keyword>Anemia of Chronic Illness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

